11/18
02:18 pm
teva
Community Routes: Access to Mental Health Care [Yahoo! Finance]
Low
Report
Community Routes: Access to Mental Health Care [Yahoo! Finance]
11/18
09:53 am
teva
US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug [Yahoo! Finance Canada]
Low
Report
US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug [Yahoo! Finance Canada]
11/14
11:43 am
teva
Global Plant-Based API Market Set to Reach USD 52,085.9 Million by 2034, Expected to Grow at a CAGR of 5.6% | Future Market Insights, Inc. [Yahoo! Finance]
Low
Report
Global Plant-Based API Market Set to Reach USD 52,085.9 Million by 2034, Expected to Grow at a CAGR of 5.6% | Future Market Insights, Inc. [Yahoo! Finance]
11/8
04:30 pm
teva
Teva to Present at the Jefferies London Healthcare Conference
Low
Report
Teva to Present at the Jefferies London Healthcare Conference
11/8
10:59 am
teva
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now? [Yahoo! Finance]
Low
Report
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now? [Yahoo! Finance]
11/7
02:19 am
teva
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Highlights: Strong Revenue ... [Yahoo! Finance]
Low
Report
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Highlights: Strong Revenue ... [Yahoo! Finance]
11/6
11:53 am
teva
Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
11/6
11:24 am
teva
Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
Low
Report
Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
11/6
07:00 am
teva
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
Medium
Report
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
11/4
01:44 pm
teva
Teva Pharmaceutical Industries (TEVA) Upgraded to Strong Buy: What Does It Mean for the Stock? [Yahoo! Finance]
Low
Report
Teva Pharmaceutical Industries (TEVA) Upgraded to Strong Buy: What Does It Mean for the Stock? [Yahoo! Finance]
11/1
03:09 pm
teva
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition [Yahoo! Finance]
Low
Report
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition [Yahoo! Finance]
11/1
03:05 pm
teva
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
Low
Report
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
11/1
03:00 pm
teva
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as
Low
Report
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as
11/1
10:55 am
teva
Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS [Yahoo! Finance]
Low
Report
Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS [Yahoo! Finance]
10/31
07:29 am
teva
Teva Statement on European Commission Decision; Company to Appeal
Low
Report
Teva Statement on European Commission Decision; Company to Appeal
10/28
12:46 pm
teva
Medincell Announces Participation in Leading Investor Conferences [Yahoo! Finance]
Low
Report
Medincell Announces Participation in Leading Investor Conferences [Yahoo! Finance]
10/28
06:54 am
teva
Brain Health Supplements Market to hit USD 19.3 billion by 2032, says Global Market Insights Inc. [Yahoo! Finance]
Low
Report
Brain Health Supplements Market to hit USD 19.3 billion by 2032, says Global Market Insights Inc. [Yahoo! Finance]
10/26
08:55 am
teva
Investors in Teva Pharmaceutical Industries (NYSE:TEVA) have seen impressive returns of 120% over the past year [Yahoo! Finance]
Low
Report
Investors in Teva Pharmaceutical Industries (NYSE:TEVA) have seen impressive returns of 120% over the past year [Yahoo! Finance]
10/25
11:48 am
teva
Wall Street Analysts Predict a 25.1% Upside in Teva Pharmaceutical Industries (TEVA): Here's What You Should Know [Yahoo! Finance]
Low
Report
Wall Street Analysts Predict a 25.1% Upside in Teva Pharmaceutical Industries (TEVA): Here's What You Should Know [Yahoo! Finance]
10/23
11:14 am
teva
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock? [Yahoo! Finance]
Low
Report
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock? [Yahoo! Finance]
10/23
11:14 am
teva
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year? [Yahoo! Finance]
Low
Report
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year? [Yahoo! Finance]
10/23
09:40 am
teva
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Barclays PLC from $22.00 to $25.00. They now have an "overweight" rating on the stock.
Low
Report
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Barclays PLC from $22.00 to $25.00. They now have an "overweight" rating on the stock.
10/23
01:00 am
teva
Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt [Seeking Alpha]
Low
Report
Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt [Seeking Alpha]
10/22
06:42 pm
teva
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory [Yahoo! Finance]
Low
Report
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory [Yahoo! Finance]
10/22
07:00 am
teva
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Low
Report
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)